Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CSTL vs NDRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CSTL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

CSTL Overall Winner 6-Pillar Tally: CSTL 4 – 1 NDRA (1 Tie) Matrix Metrics: CSTL 5 – 3 NDRA

As of Nov 16, 2026, Castle Biosciences, Inc. (CSTL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CSTL carries a Unified Composite Score of 49.3/100 (HOLD) at $32.75 (N/M Forward P/E, -7.4% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CSTL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.9); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CSTL vs NDRA
CSTL NASDAQ Head-to-Head Winner
Castle Biosciences, Inc. Common Stock
Services-Medical Laboratories
$32.75
-3.08% 1D
Market Cap $1.0B
TTM Revenue $377M
Forward P/E N/M
Beta / 30D Vol 1.18β · 57% Vol
Unified Composite Score
49.3 / 100 HOLD
Tech 25.0 Fund 41.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.9 · SMA20: $34.52 · SMA50: $34.35
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32

6-Pillar Scorecard Institutional Category Breakdown (CSTL 4 – 1 NDRA)

Columns: Metric · CSTL · NDRA
1. Valuation Multiples CSTL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 2.8x N/M
2. Growth & Scale CSTL
Revenue Growth (YoY) +23.9% +0.0%
Earnings Growth (YoY) -51.6% +0.0%
TTM Revenue (USD) $377M N/A
Market Cap $1.0B $6.6M
3. Profitability & Quality NDRA
Gross Margin 77.1% N/A
Operating Margin -7.4% 0.0%
Net Profit Margin -6.1% 0.0%
Return on Equity (ROE) -4.9% -152.0%
4. Balance Sheet & Cash Flow CSTL
Cash Generation (TTM) -$12M EBITDA -$8.0M
Cash Flow Margin -3.2% EBITDA Mgn N/A
Net Cash / Leverage $15.55 Book/Sh · -4.9% ROE $104,744 Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 41.4% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CSTL
OpEx & R&D Intensity 84.5% of Rev ($319M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CSTL (5) vs NDRA (3)
Institutional Metric CSTL NDRA Criterion Row Edge
Market Capitalization
Scale
$1.0B $6.6M Larger Scale CSTL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+23.9% +0.0% Higher Growth CSTL
Operating Margin (TTM)
Profitability
-7.4% 0.0% Higher Margin NDRA
Net Profit Margin
Profitability
-6.1% 0.0% Higher Margin NDRA
Return on Equity (ROE)
Capital Efficiency
-4.9% -152.0% Higher ROE CSTL
52-Week Range Position
Momentum
57% ($18–$44) 37% ($3–$7) Stronger Trend CSTL
Beta / 30D Volatility
Risk Regime
1.18β · 57% Vol 0.71β · 48% Vol Lower Realized Risk NDRA
Unified Institutional Score
Composite Signal
49.3 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite CSTL
Trailing 12M Revenue (USD)
Operating Scale
$377M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($15.55 Book/Sh · -4.9% ROE) -$8.0M ($104,744 Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CSTL +9.22 pp
CSTL: +2.47% · NDRA: -6.75%
3M Horizon CSTL +14.81 pp
CSTL: +12.81% · NDRA: -2.0%
6M Horizon CSTL +87.81 pp
CSTL: +69.51% · NDRA: -18.3%
1Y Horizon CSTL +28.7 pp
CSTL: -4.02% · NDRA: -32.72%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CSTL vs NDRA. Trailing 12-month operating profitability (CSTL -7.4% vs NDRA 0.0%) and valuation multiples (CSTL N/M vs NDRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CSTL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$377M
Gross Margin77.1%
Op. Margin-7.4%
ROE / Fwd P/E-4.9% · N/M
NDRA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-152.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CSTL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 41.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CSTL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CSTL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.0B market capitalization and -7.4% operating margin.
OpEx & R&D Reinvestment 84.5% of Rev ($319M)
90D Engineering Disclosures 0 Published
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CSTL vs NDRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Castle Biosciences, Inc. (CSTL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CSTL carries a Unified Composite Score of 49.3/100 (HOLD) at $32.75 (N/M Forward P/E, -7.4% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CSTL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.9); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CSTL leads the Growth & Scale pillar: CSTL posts +23.9% YoY revenue growth and -51.6% YoY earnings growth on $377M TTM revenue (77.1% gross margin, -7.4% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CSTL generates $377M in USD-normalized revenue versus N/A for NDRA. In operating R&D and SG&A reinvestment, CSTL deploys 84.5% of Rev ($319M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.

CSTL screens cheaper on headline valuation multiples. CSTL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (-3.2% EBITDA margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CSTL (-4.9% ROE) versus NDRA (-152.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CSTL carries 41.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 57% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.